乌提德隆抑制PDAC生长,并通过诱导免疫细胞死亡来增强凝治疗
Jingyi Zhou1,2, Kangnan Zhang3,4, Chuan Liu1
1Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
iScience
|June 18, 2025
概括
微管稳定剂乌蒂德隆 (UTD1) 在胰腺管道腺癌 (PDAC) 方面表现有前途. 将UTD1与凝胺 (GEM) 结合起来可以增强抗瘤效果,并触发免疫细胞死亡,改善患者的生存率.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 胰腺管腺癌 (PDAC) 仍然是一个具有挑战性的恶性瘤,治疗选择有限.
- 微管稳定剂,如Utidelone (UTD1),在固体瘤中表现出抗瘤活性,但它们在PDAC中的有效性尚未得到充分证实.
研究的目的:
- 为了研究Utidelone (UTD1) 作为单一药物和结合gemcitabine (GEM) 治疗胰腺管腺癌 (PDAC) 的治疗潜力.
- 阐明UTD1和GEM联合疗效背后的机制,重点关注细胞死亡诱导和免疫调节.
主要方法:
- 试验室研究包括CCK8,殖民地形成,细胞亡和细胞循环测定.
- 在体内研究中,使用了异种移植和免疫能力强的KPC小鼠模型.
- 免疫表型分析评估了T细胞透和PD-L1表达.
主要成果:
- 乌提德 (UTD1) 证明了剂量依赖的抑制PDAC细胞增殖,诱导细胞亡和G2/M细胞周期停止.
- 结合UTD1和gemcitabine (GEM) 在体外和体外模型中显著提高了抗瘤疗效.
- UTD1 + GEM治疗增加了免疫细胞死亡 (ICD) 的标记物,促进了CD4 + / CD8 + T细胞透,并在KPC模型中调高了PD-L1表达,从而改善了生存率和减少了瘤负担.
结论:
- 乌提德隆 (UTD1) 在PDAC模型中表现出显著的抗瘤活性,可能通过触发免疫细胞死亡 (ICD) 来实现.
- UTD1和gemcitabine (GEM) 的组合通过增强ICD和调节瘤免疫微环境,为PDAC提供了增强的治疗效益.
- UTD1代表了对PDAC的有希望的治疗策略,特别是与化疗结合使用,这需要进一步的临床研究.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K